Storia in 4 fonti

‘Paradigm-shifting’ treatment for pediatric diabetes cleared by FDA

Yale’s Kevan Herold was the senior investigator on a clinical trial which showed that the drug teplizumab — recently approved for pediatric patients with Stage 3 Type 1 diabetes — delays the progression of the disease.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

news.yale.eduStai leggendo1 mese fa

‘Paradigm-shifting’ treatment for pediatric diabetes cleared by FDA

originale

Timeline cronologica

martedì 23 giugno 2026·dailymail.com
Drug that delays type 1 diabetes by up to three years approved by NHS
The National Institute for Health and Care Excellence (Nice) has approved teplizumab, with Diabetes UK saying it 'marks the start of a new age of treatment'.
martedì 23 giugno 2026·independent.co.uk
Experts hail ‘new age of diabetes treatment’ as drug approved on NHS
Teplizumab is approved for children aged eight and over

‘Paradigm-shifting’ treatment for pediatric diabetes cleared by FDA

Confronto fonti

‘Paradigm-shifting’ treatment for pediatric diabetes cleared by FDA

Timeline cronologica

Drug that delays type 1 diabetes by up to three years approved by NHS

Experts hail ‘new age of diabetes treatment’ as drug approved on NHS

Experts hail ‘new age of diabetes treatment’ as drug approved on NHS

Drug that delays type 1 diabetes by up to three years approved by NHS

Drug that delays onset of type 1 diabetes approved in England and Wales

NHS approves breakthrough drug that can delay type 1 diabetes for years

Drug that delays onset of type 1 diabetes approved in England and Wales

‘Paradigm-shifting’ treatment for pediatric diabetes cleared by FDA